156 related articles for article (PubMed ID: 15592724)
1. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.
Tremlett H; Oger J
J Neurol; 2004 Nov; 251(11):1297-303. PubMed ID: 15592724
[TBL] [Abstract][Full Text] [Related]
2. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.
Francis GS; Grumser Y; Alteri E; Micaleff A; O'Brien F; Alsop J; Stam Moraga M; Kaplowitz N
Drug Saf; 2003; 26(11):815-27. PubMed ID: 12908850
[TBL] [Abstract][Full Text] [Related]
3. Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
Tamura S; Warabi Y; Matsubara S
J Clin Pharm Ther; 2012 Dec; 37(6):724-5. PubMed ID: 22642738
[TBL] [Abstract][Full Text] [Related]
4. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.
Chan S; Kingwell E; Oger J; Yoshida E; Tremlett H
Mult Scler; 2011 Mar; 17(3):361-7. PubMed ID: 21148660
[TBL] [Abstract][Full Text] [Related]
5. Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.
Byrnes V; Afdhal N; Challies T; Greenstein PE
Ann Hepatol; 2006; 5(1):56-9. PubMed ID: 16531969
[TBL] [Abstract][Full Text] [Related]
6. Liver injury associated with the beta-interferons for MS: a comparison between the three products.
Tremlett HL; Yoshida EM; Oger J
Neurology; 2004 Feb; 62(4):628-31. PubMed ID: 14981183
[TBL] [Abstract][Full Text] [Related]
7. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes.
Tremlett HL; Oger J
Mult Scler; 2004 Jun; 10(3):298-301. PubMed ID: 15222695
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune events during interferon beta-1b treatment for multiple sclerosis.
Durelli L; Ferrero B; Oggero A; Verdun E; Bongioanni MR; Gentile E; Isoardo GL; Ricci A; Rota E; Bergamasco B; Durazzo M; Saracco G; Biava MA; Brossa PC; Giorda L; Pagni R; Aimo G
J Neurol Sci; 1999 Jan; 162(1):74-83. PubMed ID: 10064173
[TBL] [Abstract][Full Text] [Related]
9. Propafenone-induced liver injury.
Spinler SA; Elder CA; Kindwall KE
Ann Pharmacother; 1992; 26(7-8):926-8. PubMed ID: 1354511
[TBL] [Abstract][Full Text] [Related]
10. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
[TBL] [Abstract][Full Text] [Related]
11. Results from a 2-year centralized tolcapone liver enzyme monitoring program.
Lew MF; Kricorian G
Clin Neuropharmacol; 2007; 30(5):281-6. PubMed ID: 17909306
[TBL] [Abstract][Full Text] [Related]
12. Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea.
Kim HS; Lee SH; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Kim SH; Choi IY; Yoon KH; Kim JH
J Clin Pharm Ther; 2016 Jun; 41(3):266-72. PubMed ID: 27015878
[TBL] [Abstract][Full Text] [Related]
13. The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon.
Capone F; De Vincentis A; Ferraro E; Rossi M; Motolese F; Picardi A; Giannetti B; Di Battista G; Vespasiani-Gentilucci U; Di Lazzaro V
Clin Neurol Neurosurg; 2020 Oct; 197():106166. PubMed ID: 32877766
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of hepatic function in new cases of pulmonary tuberculosis due to the use of standard chemotherapy regimens I and IIB].
Abdullaev RIu; Vaniev EV; Kaminskaia GO; Vasil'eva IA; Komissarova OG
Probl Tuberk Bolezn Legk; 2009; (2):57-61. PubMed ID: 19382645
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta treatment for multiple sclerosis: persisting questions.
Goodkin DE
Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
[TBL] [Abstract][Full Text] [Related]
16. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis.
Uzawa A; Mori M; Hayakawa S; Masuda S; Kuwabara S
Eur J Neurol; 2010 May; 17(5):672-6. PubMed ID: 20039942
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced liver injury.
Abboud G; Kaplowitz N
Drug Saf; 2007; 30(4):277-94. PubMed ID: 17408305
[TBL] [Abstract][Full Text] [Related]
18. A descriptive analysis of aspartate and alanine aminotransferase rise and fall following acetaminophen overdose.
Curtis RM; Sivilotti ML
Clin Toxicol (Phila); 2015 Nov; 53(9):849-55. PubMed ID: 26294195
[TBL] [Abstract][Full Text] [Related]
19. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
[TBL] [Abstract][Full Text] [Related]
20. Liver injury associated with the beta-interferons for MS.
Francis GS; Kaplowitz N; Alteri E
Neurology; 2004 Sep; 63(6):1142-3; author reply 1142-3. PubMed ID: 15457586
[No Abstract] [Full Text] [Related]
[Next] [New Search]
